RxDoctor Payments Data

Arpit Shah, DO

Cardiovascular Disease · Chicago, ILNPI 1346498292

Payments from drug & device makers

$1,309in general payments, 2019–2025

Across 45 payments — averaging $29.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sunovion Pharmaceuticals Inc.$262
  • Boston Scientific$183
  • Bayer$177
  • Penumbra, Inc.$143
  • Novartis$122
  • AstraZeneca$109
  • plus $313 from 12 others

What the payments were for

  • Food & beverage$1,309100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,309 in reported general payments places this provider in the 45th percentile of 932 cardiovascular disease providers in Illinois.

See all cardiovascular disease providers in Illinois

Medicare billing

Part B allowed, 2024
$111,838
Medicare patients
372
Services billed
1,419

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide11$6,554
JardianceEmpagliflozin13$4,403
Levetiracetam26$1,975
Atorvastatin Calcium82$1,231
Albuterol Sulfate HfaAlbuterol Sulfate19$780
Mirtazapine12$584
Nifedipine ErNifedipine33$448
Carvedilol45$369
Potassium Chloride29$362
Tamsulosin Hcl15$308
Furosemide41$197
Donepezil Hcl14$190
Montelukast Sodium13$156
Famotidine32$146
ClopidogrelClopidogrel Bisulfate14$139

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Boehringer IngelheimJardiance$26$4,40313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 932 cardiovascular disease providers in Illinois.

Other cardiovascular disease in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →